Document is current
Any future updates will be listed below
-
Authors
Sinha, Meenal https://orcid.org/0000-0002-4008-4080
Zhang, Li
Subudhi, Sumit
Chen, Brandon
Marquez, Jaqueline
Liu, Eric V
Allaire, Kate
Cheung, Alexander
Ng, Sharon
Nguyen, Christopher
Friedlander, Terence W
Aggarwal, Rahul
Spitzer, Matthew
Allison, James P
Small, Eric J
Sharma, Padmanee
Fong, Lawrence
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01804465 at ClinicalTrials.govnct01804465 at ClinicalTrials.govDocuments that mention this clinical trial
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2020-002254
Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2025-012690
Documents that mention this clinical trial
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2020-002254
Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2025-012690
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA223484, U01CA233100, and U01CA244452.)
Prostate Cancer Foundation (Prostate Cancer Foundation Challenge Grant)
- License Information
